ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
A key tool for monitoring breast cancer patients under neoadjuvant treatment is the identification of reliable predictive markers. Ki67 has been identified as a prognostic and predictive marker in ER-positive breast cancer. Ninety ER-positive, HER2 negative locally advanced breast cancer patients re...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
IOS Press
2020-06-01
|
Series: | Tumor Biology |
Online Access: | https://doi.org/10.1177/1010428320925301 |
id |
doaj-d4ede271e5ed4467a91a318342a85a54 |
---|---|
record_format |
Article |
spelling |
doaj-d4ede271e5ed4467a91a318342a85a542021-05-02T18:35:18ZengIOS PressTumor Biology1423-03802020-06-014210.1177/1010428320925301ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatmentA Ianza0F Giudici1C Pinello2SP Corona3C Strina4O Bernocchi5M Bortul6M Milani7M Sirico8G Allevi9S Aguggini10A Cocconi11C Azzini12M Dester13V Cervoni14A Bottini15M Cappelletti16D Generali17Department of Medical, Surgery & Health Sciences, University of Trieste, Trieste, ItalyDepartment of Medical, Surgical & Health Sciences, Cattinara Teaching Hospital, University of Trieste, Trieste, ItalyDepartment of Medical, Surgical & Health Sciences, Cattinara Teaching Hospital, University of Trieste, Trieste, ItalyDepartment of Medical, Surgical & Health Sciences, Cattinara Teaching Hospital, University of Trieste, Trieste, ItalyBreast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, ItalyDepartment of Medical, Surgical & Health Sciences, Cattinara Teaching Hospital, University of Trieste, Trieste, ItalyDepartment of Medical, Surgical & Health Sciences, Cattinara Teaching Hospital, University of Trieste, Trieste, ItalyBreast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, ItalyBreast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, ItalyBreast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, ItalyBreast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, ItalyBreast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, ItalyBreast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, ItalyBreast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, ItalyBreast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, ItalyBreast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, ItalyBreast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, ItalyBreast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, ItalyA key tool for monitoring breast cancer patients under neoadjuvant treatment is the identification of reliable predictive markers. Ki67 has been identified as a prognostic and predictive marker in ER-positive breast cancer. Ninety ER-positive, HER2 negative locally advanced breast cancer patients received letrozole (2.5 mg daily) and cyclophosphamide (50 mg daily) with/without Sorafenib (400 mg/bid daily) for 6 months before undergoing surgery. Ki67 expression and tumor size measured with caliber were determined at baseline, after 30 days of treatment and at the end of treatment. Patients were assigned to a clinical response category according to Response Evaluation Criteria in Solid Tumors, both at 30 days and before surgery and further classified as high-responder and low-responder according to the median variation of Ki67 values between biopsy and 30 days and between biopsy and surgery time. The predictive role of Ki67 and its changes with regard to clinical response and survival was analyzed. No differences in terms of survival outcomes emerged between the arms of treatment, while we observed a higher percentage of women with progression or stable disease in arm with the combination containing Sorafenib (20.5% vs 7.1%, p = 0.06). Clinical complete responders experienced a greater overall variation in Ki67 when compared with partial responders and patients with progressive/stable disease (66.7% vs 30.7%, p = 0.009). High responders showed a better outcome than low responders in terms of both disease-free survival ( p = 0.009) and overall survival ( p = 0.002). ΔKi67 score evaluated between basal and residual tumor at definitive surgery showed to be highly predictive of clinical complete response, and a potential parameter to be used for predicting disease-free survival and overall survival in luminal breast cancer treated with neoadjuvant endocrine-based therapy.https://doi.org/10.1177/1010428320925301 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
A Ianza F Giudici C Pinello SP Corona C Strina O Bernocchi M Bortul M Milani M Sirico G Allevi S Aguggini A Cocconi C Azzini M Dester V Cervoni A Bottini M Cappelletti D Generali |
spellingShingle |
A Ianza F Giudici C Pinello SP Corona C Strina O Bernocchi M Bortul M Milani M Sirico G Allevi S Aguggini A Cocconi C Azzini M Dester V Cervoni A Bottini M Cappelletti D Generali ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment Tumor Biology |
author_facet |
A Ianza F Giudici C Pinello SP Corona C Strina O Bernocchi M Bortul M Milani M Sirico G Allevi S Aguggini A Cocconi C Azzini M Dester V Cervoni A Bottini M Cappelletti D Generali |
author_sort |
A Ianza |
title |
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment |
title_short |
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment |
title_full |
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment |
title_fullStr |
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment |
title_full_unstemmed |
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment |
title_sort |
δki67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment |
publisher |
IOS Press |
series |
Tumor Biology |
issn |
1423-0380 |
publishDate |
2020-06-01 |
description |
A key tool for monitoring breast cancer patients under neoadjuvant treatment is the identification of reliable predictive markers. Ki67 has been identified as a prognostic and predictive marker in ER-positive breast cancer. Ninety ER-positive, HER2 negative locally advanced breast cancer patients received letrozole (2.5 mg daily) and cyclophosphamide (50 mg daily) with/without Sorafenib (400 mg/bid daily) for 6 months before undergoing surgery. Ki67 expression and tumor size measured with caliber were determined at baseline, after 30 days of treatment and at the end of treatment. Patients were assigned to a clinical response category according to Response Evaluation Criteria in Solid Tumors, both at 30 days and before surgery and further classified as high-responder and low-responder according to the median variation of Ki67 values between biopsy and 30 days and between biopsy and surgery time. The predictive role of Ki67 and its changes with regard to clinical response and survival was analyzed. No differences in terms of survival outcomes emerged between the arms of treatment, while we observed a higher percentage of women with progression or stable disease in arm with the combination containing Sorafenib (20.5% vs 7.1%, p = 0.06). Clinical complete responders experienced a greater overall variation in Ki67 when compared with partial responders and patients with progressive/stable disease (66.7% vs 30.7%, p = 0.009). High responders showed a better outcome than low responders in terms of both disease-free survival ( p = 0.009) and overall survival ( p = 0.002). ΔKi67 score evaluated between basal and residual tumor at definitive surgery showed to be highly predictive of clinical complete response, and a potential parameter to be used for predicting disease-free survival and overall survival in luminal breast cancer treated with neoadjuvant endocrine-based therapy. |
url |
https://doi.org/10.1177/1010428320925301 |
work_keys_str_mv |
AT aianza dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT fgiudici dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT cpinello dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT spcorona dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT cstrina dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT obernocchi dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT mbortul dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT mmilani dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT msirico dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT gallevi dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT saguggini dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT acocconi dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT cazzini dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT mdester dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT vcervoni dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT abottini dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT mcappelletti dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment AT dgenerali dki67proliferationindexasindependentpredictiveandprognosticfactorofoutcomeinluminalbreastcancerdatafromneoadjuvantletrozolebasedtreatment |
_version_ |
1721488924098953216 |